文献速递临床试验与 GCP流行病学与生物统计

比较2型糖尿病患者从多次胰岛素注射治疗转换为加用伊美格列明对治疗满意度的影响(MEGMI-TS):多中心、前瞻性、随机、开放标签、平行组对照试验的研究方案

Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes (MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial.
PubMed 文献 · Trials · 2025-12-04

本研究为多中心、前瞻性、随机、开放标签、平行组对照试验,计划纳入36例糖化血红蛋白41-73 mmol/mol(6.0-8.9%)且已接受多次每日胰岛素注射至少12周的2型糖尿病患者,随机分为继续多次每日胰岛素注射组或加用伊美格列明1000 mg每日两次并停用餐时胰岛素组,干预12周,主要终点为12周后DTSQs总分变化。

要点

  • 拟纳入36例已接受多次每日胰岛素注射至少12周的2型糖尿病患者进行随机分组。
  • 干预组加用伊美格列明1000 mg每日两次并停用餐时胰岛素,对照组继续多次每日胰岛素注射,疗程12周。
  • 主要终点为12周后DTSQs总分变化,次要终点包括糖化血红蛋白、DTSQc、DEBQ等变化。

核心结论

  • 本研究将是首个在多次每日胰岛素注射治疗的2型糖尿病患者中,比较转换为长效胰岛素加伊美格列明治疗与继续多次每日胰岛素注射对治疗满意度影响的随机对照试验。

研究设计与样本

  • 多中心、前瞻性、随机、开放标签、平行组对照试验,计划纳入36例糖化血红蛋白41-73 mmol/mol(6.0-8.9%)且已接受多次每日胰岛素注射至少12周的2型糖尿病患者,随机分为继续多次每日胰岛素注射组或加用伊美格列明1000 mg每日两次并停用餐时胰岛素组,干预12周。

主要发现

  • 原文未报告研究结果,主要终点为12周后DTSQs总分变化。
  • 次要终点包括糖化血红蛋白、DTSQs分层分析、DTSQc、DEBQ及其单项评分变化、体格检查和其他实验室参数的变化。

关键数值与推荐

  • 纳入标准:糖化血红蛋白41-73 mmol/mol(6.0-8.9%),已接受多次每日胰岛素注射至少12周。
  • 干预方案:加用伊美格列明1000 mg每日两次并停用餐时胰岛素,持续12周。
  • 主要终点:12周后DTSQs总分变化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple daily insulin injection (MDI) is effective in preventing and slowing the progression of diabetic vascular complications in type 2 diabetes (T2D). However, MDI can impose various psychological and economic burdens. Some oral anti-diabetic agents can reduce such burdens and improve patient satisfaction in T2D subjects during MDI. Imeglimin is a newer anti-hyperglycemic agent with pharmacological action on both insulin secretion and resistance, and its efficacy has been demonstrated in phase III clinical trials. Considering imeglimin's action, this study examines whether reducing the number of insulin injections with imeglimin contributes to improved treatment satisfaction in subjects treated with MDI. METHODS: The study is a multicenter, prospective, randomized, open-label, parallel-group comparison trial. Thirty-six T2D subjects with glycated hemoglobin levels of 41-73 mmol/mol (6.0-8.9%) who had been treated with MDI for at least 12 weeks will be randomized to continue MDI or to receive an additional dose of imeglimin 1000 mg twice daily and discontinue bolus insulin for 12 weeks. At baseline and at the end of the study, questionnaires will be administered to assess treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire (DTSQ)) and eating behavior (Dutch Eating Behavior Questionnaire (DEBQ)); physical evaluation and biochemical analysis will be conducted; and adverse events will be recorded. The primary endpoint is the change in total DTSQ status version (DTSQs) score after 12 weeks. The secondary endpoints will consist of the mean changes in glycated hemoglobin, stratified analysis of the DTSQs, DTSQ change version (DTSQc), and DEBQ and changes in individual scores, physical examination, and other laboratory parameters. DISCUSSION: This will be the first randomized controlled trial comparing switching to long-acting insulin plus imeglimin therapy with continuing MDI in terms of efficacy on treatment satisfaction in T2D subjects treated with MDI. Asahikawa Medical University Research Ethics Committee (No. 11000290) has approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences. This study will provide new insights into the administration of imeglimin in management strategies for T2D subjects. TRIAL REGISTRATION: This protocol has been registered with the Japan Registry of Clinical Trials on 22 July 2024 [Identifier: jRCT1011240025, URL: https://jrct.niph.go.jp/latest-detail/jRCT1011240025 ] before the enrollment of the first participant.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kitsunai H, Nanbu T, Maruyama F, et al. Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes (MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial. Trials. 2025. PMID: 41345697. doi:10.1186/s13063-025-09309-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。